Dr. Xing Huang (Ph.D., Prof.), after trained in Dr. Guido Kroemer’s lab, is currently serving as a principle investigator at Zhejiang Provincial Key Laboratory of Pancreatic Disease in Zhejiang University School of Medicine. Dr. Huang, as corresponding author or/and first author, has recently published a number of research articles in high profile journals, including Molecular Cancer, Signal Transduction and Targeted Therapy, Nature Communications, Autophagy, The EMBO Journal, Cancer Immunology Research, Journal of Experimental & Clinical Cancer Research, and Oncogene. Dr. Huang has served as the Associated Editor of Molecular Medicine, Editorial Board of BMC Cancer, Heliyon, Frontiers in Nephrology and Journal of Molecular Cell Biology, Guest Editor of Frontiers in Cell and Developmental Biology and Frontiers in Oncology, as well as Reviewer of Advanced Science, JCO Precision Oncology, Journal of the National Comprehensive Cancer Network, Molecular Therapy - Nucleic Acids, Cancer Immunology Research, JCO Clinical Cancer Informatics, Theranostics, OncoImmunology and Oncogenesis. Dr. Huang has also been recognized with several awards, including the Outstanding Poster Award of National Academic Conference of Chinese Society for Cell Biology, and the Excellent Report Award of Hefei National Laboratory for Physical Sciences at the Microscale.   Dr. Xing Huang has written a few Editorial Materials for Signal Transduction and Targeted Therapy (Pancreatic tumor initiation: the potential role of IL-33, 2021), Journal for ImmunoTherapy of Cancer (Cancer environmental immunotherapy: Starving tumor cell to death by targeting TGFB on immune cell, 2021), Signal Transduction and Targeted Therapy (Eating self for not be eaten: pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation, 2020), Cellular & Molecular Immunology (Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget, 2020), and OncoImmunology (Reviving the role of MET in liver cancer therapy and vaccination: an autophagic perspective, 2020), as well as several Reviews for Signal Transduction and Targeted Therapy (Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy, 2021), Journal of Hematology & Oncology (VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy, 2020), and Frontiers in Oncology (Deubiquitinating enzyme: a potential secondary checkpoint of cancer immunity, 2020).